Drug Trial Radar · NCT06965881
Study to Evaluate the Pharmacokinetics and Safety Effects Following Coadministration of Carbamazepine or Itraconazole With Radiprodil in Healthy Adults
Last checked: Nov 19, 2026Latest source record: Nov 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
30
Actual
Start
May 8, 2025
Primary completion
Jul 8, 2025
Study completion Jul 8, 2025
Sponsor
- Lead sponsor
- GRIN Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Avance Clinical Pty Ltd.
- First posted
- May 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1, open-label, 2-part study to evaluate the effect of multiple doses of oral carbamazepine or oral itraconazole on the plasma pharmacokinetic profile of radiprodil in healthy adult participants. In addition, the safety and tolerability of radiprodil given together with oral carbamazepine or itraconazole will be assessed.
Conditions
- Tuberous Sclerosis Complex (TSC)
- Focal Cortical Dysplasia
- Other Neurological Disorders
Interventions
Radiprodil with CarbamazepineDrug
Participants will receive oral doses of Radiprodil in the range of 7.5mg to 30mg along with oral doses of Carbamazepine in the range of 100mg to 300mg twice daily over a period of 27 days.
Radiprodil with ItraconazoleDrug
Participants will receive oral doses of Radiprodil in the range of 7.5mg to 15mg along with oral doses of Itraconazole 200mg twice daily over a period of 21 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: To assess the effect of oral carbamazepine on the maximum observed plasma concentration (Cmax) of oral dosing of radiprodilTime frame: Blood samples will be collected on Days 7 to 10 and 25 to 28.
- Part B: To assess the effect of oral itraconazole on the maximum plasma concentration (Cmax) of oral dosing of radiprodilTime frame: Blood samples will be collected Days 5 to 9 and 18 to 22.
- Part A: To asses the effect of oral carbamazepine on radiprodil area under the plasma concentration-time curve from 0 to last quantifiable concentration (AUClast)Time frame: Blood samples will be collected on Days 7 to 10 and 25 to 28.
- Part B: To asses the effect of oral itraconazole on the radiprodil area under the plasma concentration-time curve from 0 to last quantifiable concentration (AUClast)Time frame: Blood samples will be collected Days 5 to 9 and 18 to 22.
- Part A: To assess the effect of oral oral carbamazepine on the area under the plasma concentration-time curve to the end of dosing interval (AUCtau) of oral dosing of radiprodilTime frame: Blood samples will be collected on Days 7 to 10 and 25 to 28
- Part B: To assess the effect of oral itraconazole on the area under the plasma concentration-time curve to the end of dosing interval (AUCtau) of oral dosing of radiprodilTime frame: Blood samples will be collected Days 5 to 9 and 18 to 22
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Q-Pharm Pty Ltd
Brisbane, Queensland, Australia
Nucleus Network Pty Ltd
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.